Samuel T. Wilkinson, MD

Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut

  • 14Articles
  • 121KReads
  • 2015–2026Active
  • 76Collaborators
  • 631Citations

About

Samuel T. Wilkinson, MD, is affiliated with the Yale Depression Research Program in the Department of Psychiatry at Yale School of Medicine. From 2015 to 2026, Wilkinson has published extensively on major depressive disorder, bipolar disorder, and posttraumatic stress disorder, with a focus on treatments such as ketamine, esketamine, electroconvulsive therapy, and psychotherapy. Research topics also include suicide prevention, Alzheimer's disease, and complementary and alternative medicine. His work often explores clinical outcomes, safety, and treatment response in patients with treatment-resistant depression and comorbid conditions.

Publications

JCP
CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial
Original Research

CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial

May 4, 2026

In patients with major depression and suicidal ideation, adding a 16-week CBT course to esketamine led to greater improvements in suicidal ideation and depression severity than esketamine alone.
, , , et al
JCP
SSRI, SNRI, or Other Antidepressant Use Not Associated With Differential Outcomes in Ketamine or Esketamine Treatment
Brief Report

SSRI, SNRI, or Other Antidepressant Use Not Associated With Differential Outcomes in Ketamine or Esketamine Treatment

April 27, 2026

No group differences were seen between concurrent oral antidepressant class and clinical outcomes in patients treated with IV ketamine or IN esketamine.
, , , et al
JCP
Ketamine and Esketamine: Is There a Meaningful Clinical Difference?
Commentary

Ketamine and Esketamine: Is There a Meaningful Clinical Difference?

September 22, 2025

The authors comment on a recent chart review by Meisner and colleagues.
,
JCP
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
Original Research

Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial

September 3, 2025

Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at...
, , , et al
JCP
Ketamine/Esketamine in Bipolar Depression in a Clinical Setting
Original Research

Ketamine/Esketamine in Bipolar Depression in a Clinical Setting

October 2, 2024

In a small sample of patients with bipolar depression treated with ketamine/esketamine, no evidence of mania or hypomania was seen during acute treatment.
, , , et al
JCP
Effects of ECT in Comorbid Depression and Dementia
Original Research

Effects of ECT in Comorbid Depression and Dementia

January 25, 2023

Limited data suggest a role for electroconvulsive therapy (ECT) in treating behavioral and psychological symptoms of dementia. Using a larger sample size than in previous reports, this study examined...
, , , et al
JCP
Ketamine in the Real World: Where Do We Go From Here?
Commentary

Ketamine in the Real World: Where Do We Go From Here?

September 14, 2022

Dr Wilkinson comments on recent data and developments in the use of ketamine for mood disorders.
JCP
Original Research

MHRU in Adults With MDD and Suicidality

September 14, 2021

Mental health care resource utilization and barriers to receiving mental health services among adults with major depression and suicidality are understudied. This study aimed to document the extensive burden...
, , , et al
JCP
Original Research

Response to Esketamine After Initial Nonresponse

July 20, 2021

Only some patients with treatment-resistant depression who ultimately respond to esketamine plus an oral antidepressant do so within the first 2 doses. This study estimated the likelihood of ultimate...
, , , et al
JCP
Original Research

ECT Among Older Adults in the US

July 7, 2020

How many older adults receive electroconvulsive therapy (ECT) for treatment-resistant depression? Among those who receive ECT, how many finish the course? What factors might predict patients' continuation of ECT?...
, , , et al
JCP
Original Research

Esketamine Nasal Spray Plus for Depression

April 28, 2020

Read a study about esketamine nasal spray (oral antidepressant) and it's long-term safety, tolerability, and efficacy for treatment-resistant depression (TRD).
, , , et al
JCP
Original Research

Ketamine as a Clinical Treatment for Mood Disorders

July 24, 2018

Ketamine, an off-label treatment for depression, can have rapid-acting antidepressant effects but is also sometimes associated with negative clinical outcomes. Do the short- and long-term benefits of ketamine treatment...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe